Nuveen’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-66,928
| Closed | -$153K | – | 3358 |
|
|
2024
Q2 | $153K | Buy |
+66,928
| New | +$256K | ﹤0.01% | 3263 |
|
|
2022
Q2 | – | Sell |
-191,665
| Closed | -$1.59M | – | 3533 |
|
|
2022
Q1 | $1.59M | Sell |
191,665
-498,605
| -72% | -$4.73M | ﹤0.01% | 2617 |
|
|
2021
Q4 | $7.05M | Buy |
690,270
+24,710
| +4% | +$315K | ﹤0.01% | 1901 |
|
|
2021
Q3 | $8.93M | Sell |
665,560
-221,080
| -25% | -$3.6M | ﹤0.01% | 1862 |
|
|
2021
Q2 | $19.5M | Buy |
886,640
+200,034
| +29% | +$4.44M | 0.01% | 1388 |
|
|
2021
Q1 | $16.5M | Buy |
686,606
+5,405
| +0.8% | +$126K | 0.01% | 1461 |
|
|
2020
Q4 | $12.3M | Buy |
681,201
+298,202
| +78% | +$4.46M | ﹤0.01% | 1563 |
|
|
2020
Q3 | $4.42M | Buy |
382,999
+215,243
| +128% | +$3.55M | ﹤0.01% | 1981 |
|
|
2020
Q2 | $4.07M | Buy |
167,756
+25,887
| +18% | +$428K | ﹤0.01% | 2014 |
|
|
2020
Q1 | $1.56M | Buy |
141,869
+10,322
| +8% | +$193K | ﹤0.01% | 2307 |
|
|
2019
Q4 | $3.48M | Sell |
131,547
-1,841
| -1% | -$43.1K | ﹤0.01% | 2178 |
|
|
2019
Q3 | $3.04M | Buy |
133,388
+19,060
| +17% | +$601K | ﹤0.01% | 2208 |
|
|
2019
Q2 | $3.5M | Buy |
+114,328
| New | +$2.41M | ﹤0.01% | 2171 |
|
Nuveen's GTHX Position: Q3 2024 in Review
Nuveen sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q3 2024, closing a stake of 66,928 shares — an estimated $153K sold.
Nuveen first reported a position in GTHX in Q2 2019 and held it in 13 quarters. The position peaked at $19.5M in Q2 2021. 0 funds tracked by Wall St. Rank hold GTHX as of Q3 2024.
- Nuveen reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
- Nuveen sold 66,928 G1 Therapeutics, Inc. Common Stock shares in Q3 2024, an estimated $153K.
- Nuveen first reported a position in G1 Therapeutics, Inc. Common Stock in Q2 2019 and held it in 13 quarters.
- Nuveen's G1 Therapeutics, Inc. Common Stock position peaked at $19.5M in Q2 2021.
- 0 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q3 2024.
Based on Nuveen's 13F filing for Q3 2024, filed 14 Nov 2024.